AIM
CORT icon

Advyzon Investment Management’s Corcept Therapeutics CORT Stock Holding History

Advyzon Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,527
Closed -$210K – 575
2025
Q3 		$210K Buy
+2,527
New +$183K 0.04% 439
2025
Q2 		– Sell
-1,896
Closed -$217K – 387
2025
Q1 		$217K Buy
+1,896
New +$115K 0.08% 236

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advyzon Investment Management's CORT Position: Q4 2025 in Review

Advyzon Investment Management sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 2,527 shares — an estimated $210K sold.

Advyzon Investment Management first reported a position in CORT in Q1 2025 and held it in 2 quarters. The position peaked at $217K in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Advyzon Investment Management reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Advyzon Investment Management sold 2,527 Corcept Therapeutics shares in Q4 2025, an estimated $210K.
  • Advyzon Investment Management first reported a position in Corcept Therapeutics in Q1 2025 and held it in 2 quarters.
  • Advyzon Investment Management's Corcept Therapeutics position peaked at $217K in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Advyzon Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.